View More Recent Stories
-
Opus Genetics (IRD) Files for 19.38M Share Offering by Selling Stockholders
-
H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)
-
Opus Genetics (IRD) Prices $20M Share Offering, Concurrent Private Placement with Proceeds of Over $20M
-
Opus Genetics (IRD) reports inducement awards
-
Opus Genetics (IRD) Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
-
Opus Genetics (IRD) Announces Updates on OPGx-LCA5 Clinical Program
-
Opus Genetics (IRD) Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330
-
H.C. Wainwright Assumes Opus Genetics (IRD) at Buy
-
Opus Genetics, Inc. (IRD) Misses Q3 EPS by 4c

